A. Makes it easier to assess adherence B. Reduces stigma associated with treatment C. Less risk for inadvertent overdose D. Predictable and consistent drug delivery E. Unsure

A. Early phase schizophrenia patients with substance abuse are less likely to adhere to treatment B. As clinicians we do a pretty good job of identifying which patients are nonadherent with treatment C. Physicians are hesitant to prescribe LAIs principally because of cost D. Patients miss about a third of doses on average over the course of a year E. Unsure

A. Using a molecular strategy which allows the formation of a less soluble salt B. Changing hepatic metabolism to slow down the removal of drug C. Using polymers and grinding methods to reduce particle size D. A and C E. Unsure

A. Engaging the patient into an ACT program B. Encouraging the patient to limit contact with family members C. Identifying barriers to treatment D. Early recognition of patients with risk factors for nonadherence/relapse E. Unsure

A. Response to prior treatment B. Employment and social activities C. Availability of psychosocial therapy options D. Barriers to adherence experienced by patient or reported by family E. Unsure